Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research.
Smith EE, Phillips NA, Feldman HH, Borrie M, Ganesh A, Henri-Bhargava A, Desmarais P, Frank A, Badhwar A, Barlow L, Bartha R, Best S, Bethell J, Bhangu J, Black SE, Bocti C, Bronskill SE, Burhan AM, Calon F, Camicioli R, Campbell B, Collins DL, Dadar M, DeMarco ML, Ducharme S, Duchesne S, Einstein G, Fisk JD, Gawryluk JR, Grossman L, Ismail Z, Itzhak I, Joshi M, Harrison A, Kroger E, Kumar S, Laforce R, Lanctot KL, Lau M, Lee L, Masellis M, Massoud F, Mitchell SB, Montero-Odasso M, Myers Barnett K, Nygaard HB, Pasternak SH, Peters J, Rajah MN, Robillard JM, Rockwood K, Rosa-Neto P, Seitz DP, Soucy JP, Trenaman SC, Wellington CL, Zadem A, Chertkow H; Canadian Consortium on Neurodegeneration in Aging Investigators.
Smith EE, et al. Among authors: kumar s.
J Prev Alzheimers Dis. 2025 Jan 31:100068. doi: 10.1016/j.tjpad.2025.100068. Online ahead of print.
J Prev Alzheimers Dis. 2025.
PMID: 39893139
Review.